CHF6333
Phase 2Small molecule
Chiesi Farmaceutici S.p.A.CHF6333 is one of 23 small molecule programs targeting Bronchiectasis. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
29 competitors in Bronchiectasis
#DrugCompanyPhaseTrials
1Theo-Dur
PfizerApproved
Cipro
BayerApproved
Tobrex
VViatris Specialty LLC
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Merrem
BB. Braun Medical Inc.
Approved
Garamycin
SSchering-Plough
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Approved
Foradil
ViatrisApproved
Qvar
SSchering-Plough
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CHF6333. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company